FGF-23 in patients with end-stage renal disease on hemodialysis

Slides:

Advertisements

Similar presentations

Renal Stress Testing in the Assessment of Kidney Disease Lakhmir S. Chawla, Claudio Ronco Kidney International Reports Volume 1, Issue 1, Pages (May.

Advertisements

Volume 62, Issue 6, Pages (December 2002)

E. Cavalier, P. Delanaye, A. Carlisi, J. -M. Krzesinski, J. -P

Beta blockers in the management of chronic kidney disease

Volume 70, Issue 3, Pages (August 2006)

Volume 73, Issue 1, Pages 3-5 (January 2008)

Anemia management in chronic kidney disease

No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease Kevin E. Chan, Ravi I. Thadhani,

End-stage renal disease in developing countries

Volume 83, Issue 3, Pages (March 2013)

Stem cells for kidney repair: useful tool for acute renal failure?

FGF23 or PTH: which comes first in CKD ?

Vitamin D deficiency and heart disease

Volume 64, Issue 6, Pages (December 2003)

Kidney transplantation in a low-resource setting: Nigeria experience

FGF23–parathyroid interaction: implications in chronic kidney disease

Volume 79, Pages S24-S27 (April 2011)

M. Fukagawa, S. Nakanishi, J.J. Kazama Kidney International

Burden of chronic kidney disease: North Africa

Comorbidity and confounding in end-stage renal disease

Ten years of progress in our understanding of uremic vascular calcification and disease: a decade summarized in 20 steps Vincent M. Brandenburg, Markus.

Volume 70, Issue 11, Pages (December 2006)

Volume 79, Pages S20-S23 (April 2011)

Use of vitamin D in chronic kidney disease patients

Volume 87, Issue 2, Pages (February 2015)

Paricalcitol therapy for secondary hyperparathyroidism in patients on maintenance hemodialysis previously treated with calcitriol: A single-center crossover.

Florian Lang, Michael Föller Kidney International

Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.

Volume 71, Issue 6, Pages (March 2007)

Volume 69, Issue 3, Pages (February 2006)

Volume 70, Issue 12, Pages (December 2006)

Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism

Volume 75, Issue 1, Pages (January 2009)

Blood pressure targets in hemodialysis patients

FGF-23 in patients with end-stage renal disease on hemodialysis

Fructose intake as a risk factor for kidney stone disease

P. Urena Torres, G. Friedlander, M.C. de Vernejoul, C. Silve, D. Prié

Volume 56, Issue 2, Pages (August 1999)

Extracorporeal therapy in sepsis: are we there yet?

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 87, Issue 3, Pages (March 2015)

Alternate-day dialysis may be needed for hemodialysis patients

Non–high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease Yoshiki Nishizawa,

Volume 75, Issue 9, Pages (May 2009)

Volume 81, Issue 9, Pages (May 2012)

Volume 78, Issue 4, Pages (August 2010)

Fibroblast growth factor 23: the making of a hormone

Volume 73, Issue 9, Pages (May 2008)

Volume 64, Issue 2, Pages (August 2003)

Latest findings in phosphate homeostasis

Current status of maintenance hemodialysis in Beijing, China

The Iranian model of living renal transplantation

Pablo A. Ureña Torres, Marc De Broe Kidney International

Elevated plasma F2-isoprostanes in patients on long-term hemodialysis

Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction Malcolm F. Hand, William G. Haynes, David J.

Volume 80, Issue 10, Pages (November 2011)

Is complement a target for therapy in renal disease?

Recent developments in the management of secondary hyperparathyroidism

Volume 70, Issue 10, Pages (November 2006)

The ins and outs of phosphate homeostasis

Diagram of the mechanisms involved in limiting the ability of the kidney to maintain the levels of 1,25-dihydroxyvitamin D in chronic kidney disease (CKD).

Volume 74, Issue 10, Pages (November 2008)

Volume 61, Issue 6, Pages (June 2002)

Marta Christov, Harald Jüppner Kidney International

Volume 83, Issue 1, Pages (January 2013)

Ronen Levi, Justin Silver Kidney International

Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies Lei-Shi Li, Zhi-Hong Liu Kidney International

Volume 86, Issue 2, Pages (August 2014)

Volume 64, Pages S131-S136 (November 2003)

Presentation transcript:

FGF-23 in patients with end-stage renal disease on hemodialysis Yasuo Imanishi, Masaaki Inaba, Kiyoshi Nakatsuka, Kyoko Nagasue, Senji Okuno, Asami Yoshihara, Masakazu Miura, Akimitsu Miyauchi, Keisuke Kobayashi, Takami Miki, Tetsuo Shoji, Eiji Ishimura, Yoshiki Nishizawa Kidney International Volume 65, Issue 5, Pages 1943-1946 (May 2004) DOI: 10.1111/j.1523-1755.2004.00604.x Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 1 Simple regression analysis of factors correlating with plasma fibroblast growth factor (FGF)-23 levels on maintenance hemodialysis. Abbreviations are: FGF, fibroblast growth factor; PTH, parathyroid hormone; cCa, corrected calcium. Kidney International 2004 65, 1943-1946DOI: (10.1111/j.1523-1755.2004.00604.x) Copyright © 2004 International Society of Nephrology Terms and Conditions